Prescription Drug Monitoring Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jul 25, 2019)
Prescription Drug Monitoring Act of 2019
This bill expands the notification and reporting requirements with respect to potentially addictive prescription drugs for states receiving funds for a Prescription Drug Monitoring Program (PDMP). Dispensers of these drugs, which includes substances listed in schedule II, III, or IV of the Controlled Substances Act, must consult with the PDMP before starting treatment involving such drugs and report each prescription of such drugs to the PDMP within 24 hours.
The state agency administering a PDMP must analyze reported data for patterns of controlled substance misuse or abuse and provide certain information to law enforcement, the public, and other states.
What just happenedJul 26, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJul 25, 2019
- Jul 26, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jul 25, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jul 25, 2019IntroReferralIntro-H
Introduced in House
- Jul 25, 2019IntroReferral1000
Introduced in House